VALUE CHAIN INSIGHTS

VALUE CHAIN INSIGHTS

  • Posted in: Value Chain Insights

    This year thus far has seen several high-profile deals and expansion moves in the contract development and manufacturing ...

  • Posted in: Value Chain Insights

    Biomanufacturing is a leading area of investment for the pharmaceutical majors. So what are the leading projects announced, ...

  • Posted in: Value Chain Insights

    Kåre Schultz, now president and CEO of H. Lundbeck A/S, has been appointed president and CEO of Teva Pharmaceutical Industries. ...

  • Posted in: Value Chain Insights

     The oncology sector is the largest therapeutic sector in the pharmaceutical industry. So what is in store for the global ...

  • Posted in: Value Chain Insights

    Batch processing is the historical and dominant form of manufacturing in the pharmaceutical industry, but continuous ...

  • Posted in: Value Chain Insights

    Thermo Fisher Scientific has completed its $7.2-billion acquisition of Patheon. So what is the impact for Thermo, Patheon, ...

  • Posted in: Value Chain Insights

    Although the future of healthcare reform is unclear, debates on drug pricing continue. So what should be on the radar ...

  • Posted in: Value Chain Insights

    Precision medicines, defined as a medical approach that proposes to prevent and treat disease based upon a person's unique ...

  • Posted in: Value Chain Insights

    Emma Walmsley, who became CEO of GlaxoSmithKline (GSK) on April 1, highlighted the priorities of the company following ...

  • Posted in: Value Chain Insights

    Healthcare reform is taking center stage in US policy-making and debates. So what should be on the radar for the pharmaceutical ...

  • Posted in: Value Chain Insights

    The market for active pharmaceutical ingredients (APIs) is approximately $140 billion and is projected to reach nearly ...

  • Posted in: Value Chain Insights

    A recent PwC report of more than 1,200 global executives and business leaders examined how top companies are meeting innovation ...

  • Posted in: Value Chain Insights

    Pharmaceutical industry leaders are calling for an orderly implementation relating to the regulation, manufacture, and ...

  • Posted in: Value Chain Insights

    The global biotechnology industry showed a slowdown in 2016. So what do the numbers show? A recent analysis by EY ...

  • Posted in: Value Chain Insights

    This year thus far has seen several high-profile deals in the pharmaceutical outsourcing market. So what moves should ...

  • Posted in: Value Chain Insights

    Johnson &Johnson's $30-billion buy of Actelion is the leading deal thus far in 2017, but what other deals have made the ...

  • Posted in: Value Chain Insights

    Johnson & Johnson (J&J) has completed its $30-billion acquisition of the Swiss pharmaceutical company, Actelion. So what ...

  • Posted in: Value Chain Insights

    As we reach the mid-point of 2017, what has been the top developments for new molecular entities (NMEs)? DCAT Value ...

  • Posted in: Value Chain Insights

    A recent US Supreme Court ruling opens a more favorable pathway for biosimilar launches in the US, but the US still trails ...

  • Posted in: Value Chain Insights

    Consolidation and tightening healthcare budgets in the European Union are key factors influencing growth in the European ...

  • Posted in: Value Chain Insights

    Pharmaceutical companies are at the annual meeting of the American Society of Clinical Oncology (ASCO) to highlight key ...

  • Posted in: Value Chain Insights

    A recent study by Deloitte surveyed C-suite executives to better understand how they view their organizations' capabilities ...

  • Posted in: Value Chain Insights

    A recent study by the investment firm, Lazard Partners, of more than 200 healthcare executives and 80 healthcare investors, ...

  • Posted in: Value Chain Insights

    Emma Walmsley, who became CEO of GlaxoSmithKline (GSK) on April 1, is leading a company that is seeking to get better ...

  • Posted in: Value Chain Insights

    A recent report by QuintilesIMS, commissioned by the European Commission, examines the market penetration and pricing ...

  • Posted in: Value Chain Insights

    Thermo Fisher Scientific has agreed to acquire Patheon for $7.2 billion, inclusive of approximately $2.0 billion of net ...

  • Posted in: Value Chain Insights

    Sourcing, procurement, and supply management professionals are faced with an ongoing challenge: reduce costs while adding ...

  • Posted in: Value Chain Insights

    US spending on prescription medicines fell in 2016 as competition intensified among manufacturers and payers ramped up ...

  • Posted in: Value Chain Insights

    With a new Commissioner of the US Food and Drug Administration pending and budget battles brewing, what may be in store ...

  • Posted in: Value Chain Insights

    The pharmaceutical industry had 27 mergers and acquisitions (M&A) in the first quarter of 2017 with a total transaction ...

  • Posted in: Value Chain Insights

    The UK's Medicines and Healthcare products Regulatory Agency (MHRA) released a report to highlight a proposed model for ...

  • Posted in: Value Chain Insights

    A recent analysis by PwC of 1,500 executives across 30 industries shows that the most successful companies make risk ...

  • Posted in: Value Chain Insights

    Through early April, the FDA's Center for Drug Evaluation and Research had approved 13 new molecular entities (NMEs), ...

  • Posted in: Value Chain Insights

    Which drugs entering the market are poised as blockbusters? DCAT Value Chain Insights examines the contenders for this ...

  • Posted in: Value Chain Insights

    In November 2016, the FDA issued a revised draft guidance to gain feedback on its quality metrics program, which included ...

  • Posted in: Value Chain Insights

    First-time generic drugs are an important measure of the new generic drugs entering the US market. So how did the US ...

  • Posted in: Value Chain Insights

    Senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) highlighted ...

  • Posted in: Value Chain Insights

    Kevin Daley Director, Pharmaceuticals Novasep Kevin Daley, Director, Pharmaceuticals, ...

  • Posted in: Value Chain Insights

    Rudolf Hanko, PhD CEO, Siegfried AG Rudolf Hanko, PhD, Chief Executive Officer ...

  • Posted in: Value Chain Insights

    Andreas Stolle, PhD Vice President, API Process Development Services Patheon ...

  • Posted in: Value Chain Insights

    Giorgio Bertolini Senior Vice President, Research & Development, Chemistry, Olon S.p.A. ...

  • Posted in: Value Chain Insights

    James Mish President & CEO Noramco James Mish, President and CEO of Noramco, ...

  • Posted in: Value Chain Insights

    Kimberly McClintock Executive Vice President, Metrics Contract Services Mayne Pharma ...

  • Posted in: Value Chain Insights

    Megan Williamson Vice President, Injection Systems Datwyler The Datwyler ...

  • Posted in: Value Chain Insights

    Mark Mitchnick, MD CEO Lubrizols Particle Sciences Mark Mitchnick, MD, Chief ...

  • Posted in: Value Chain Insights

    Mimoun Ayoub, PhD Director, Global Peptides, Oligonucleotides, Lipids, Carbohydrates & Injectables ...

  • Posted in: Value Chain Insights

    Robert Broeze, PhD Chief Business Officer CMC Biologics Robert Broeze, PhD, ...

  • Posted in: Value Chain Insights

    Elliott Berger   Vice President, Global Strategy Catalent Pharma Solutions ...

  • Posted in: Value Chain Insights

    Marc Sauer Vice President, Research and Development BioVectra In 2017, BioVectra ...

  • Posted in: Value Chain Insights

    From tracking pharmaceutical industry growth to evaluating sourcing and supply strategies for small molecules, biologics, ...

  • Posted in: Value Chain Insights

    Contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) have been ...

  • Posted in: Value Chain Insights

    Emerging pharma companies are an important source of innovation for the pharmaceutical industry, but how is this sector ...

  • Posted in: Value Chain Insights

    How can pharmaceutical companies take sourcing, procurement, and supply management to the next level?. Pharmaceutical ...

  • Posted in: Value Chain Insights

    At a recent Congressional hearing, representatives from the FDA and the Association for Accessible Medicines (formerly ...

  • Posted in: Value Chain Insights

    Driven by new product development for biopharmaceuticals, contract manufacturing organizations (CMOs) are expanding. So ...

  • Posted in: Value Chain Insights

    As pharmaceutical companies intensify their product development in biologics, their supply requirements increase as well. ...

  • Posted in: Value Chain Insights

    In what segments are contract manufacturers expanding development and manufacturing capabilities? DCAT Value Chain Insights ...

  • Posted in: Value Chain Insights

    The Biosimilars Council, a division of the Association for Accessible Medicines (formerly the Generic Pharmaceutical ...

  • Posted in: Value Chain Insights

    Pharmaceutical companies, CDMOs, CMOs, and excipient producers need to continually evaluate their strategies, technologies, ...

  • Posted in: Value Chain Insights

    Potential mega-mergers put Pfizer in the headlines over the past several years, but will that be the strategy of the ...

  • Posted in: Value Chain Insights

    Trade is a large issue in current public policy debates, particularly with the new US Presidential Administration. So what ...

  • Posted in: Value Chain Insights

    Effective communication is an imperative for successful business relationships, but are you sending the right signals ...

  • Posted in: Value Chain Insights

    In the battle of small molecules versus biologics, how have new small molecules fared? DCAT Value Chain Insights examines ...

  • Posted in: Value Chain Insights

    Are pharmaceutical companies outsourcing more of their development and manufacturing activities, and what can be expected ...

  • What is Next for Teva?

    Posted in: Value Chain Insights

    Teva Pharmaceutical Industries announced this week that its current chief executive, Erez Vigodman, was stepping down ...

  • Posted in: Value Chain Insights

    With the rise of biologic-based drug development, the number of parenteral drugs under development and receiving approval ...

  • Posted in: Value Chain Insights

    A recent PwC study of nearly 1,400 CEOs asked for their input on the impact of globalization and technology on business ...

  • Posted in: Value Chain Insights

    So how will the pharmaceutical industry fare in 2017 and beyond? A DCAT Week '17 education program, Pharma Industry ...

  • Posted in: Value Chain Insights

    Using a risk-based inspection scheme, the US Food and Drug Administration has made bringing to parity inspections of ...

  • Posted in: Value Chain Insights

    Blockchain technology has all the buzz in the banking and financial services industries, but does it have potential for ...

  • Posted in: Value Chain Insights

    Health ministers from more than 35 countries of the Organisation for Economic Co-operation and Development (OECD) met this ...

  • Posted in: Value Chain Insights

    From healthcare reform, to slowing global pharmaceutical industry growth, to a possible showdown in biosimilars, DCAT ...

  • Posted in: Value Chain Insights

    Following two consecutive years of high numbers in new molecular entity (NME) approvals by the US Food and Drug Administrations ...

  • Posted in: Value Chain Insights

    Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33% from 2016 levels even as annual growth ...

  • Posted in: Value Chain Insights

    A recent study by A.T. Kearney provides benchmarks for a proprietary metric, return on supply management assets, and ...

  • Posted in: Value Chain Insights

    The FDA has issued final guidance regarding implementation of the Drug Supply Chain Security Act (DSCSA), legislation ...

  • Posted in: Value Chain Insights

    As 2016 comes to a close, what have been the top stories of 2016 thus far? DCAT Value Chain Insights (VCI) examines ...

  • Posted in: Value Chain Insights

    Johnson & Johnson (J&J) has confirmed that it is in preliminary discussions with Actelion Pharmaceuticals, an Allschwil, ...

  • Posted in: Value Chain Insights

    Data and the analysis of that data guide drug development, product decisions, dosing and patient use, and pricing and ...

  • Posted in: Value Chain Insights

    Gilead Sciences rose to the top of the pharmaceutical industry company rankings on the strength of its hepatitis C franchise, ...

  • Posted in: Value Chain Insights

    Patent pendency, the time it takes for patent review and approval, is an important measure of innovation, and significant ...

  • Posted in: Value Chain Insights

    As the number of and diversity of drug candidates enter pharmaceutical companies' pipelines, strategies to overcome issues ...

  • Posted in: Value Chain Insights

    Much attention has been given to personalized medicines as a means of transforming healthcare with potentially more effective ...

  • Posted in: Value Chain Insights

    Orphan drugs have dominated new drug approvals over the past several years, but are they delivering market success? Facing ...

  • Posted in: Value Chain Insights

    A recent benchmarking analysis by The Hackett Group outlines the performance advantages of world-class procurement organizations. ...

  • Posted in: Value Chain Insights

    While most industry analysis touts the importance of digital technologies in meeting business goals, has this really ...

  • Posted in: Value Chain Insights

    Overall venture-capital (VC) activity declined in the third quarter of 2016, both in the number of deals and in dollars, ...

  • Posted in: Value Chain Insights

    Stefan Oschmann, chairman of the Executive Board and CEO of Merck KGaA, recently outlined the company's progress in meeting ...

  • Posted in: Value Chain Insights

    Small molecules are the dominant modality for active pharmaceutical ingredients (APIs), an important measure for fine ...

  • Posted in: Value Chain Insights

    Regulatory agencies in the US, European Union, and Japan are moving forward with plans to achieve greater cooperation ...

  • Posted in: Value Chain Insights

    Pfizer announced this week that the company will not pursue separating the company into two independent companies, one ...

  • Posted in: Value Chain Insights

    Following its proposed $66-billion acquisition of the agrochemical and seeds company, Monsanto, Bayer has reaffirmed ...

  • Posted in: Value Chain Insights

    GlaxoSmithKline's (GSK) has announced that Emma Walmsley, currently chief executive officer (CEO) of GSKs Consumer Healthcare ...

  • Posted in: Value Chain Insights

    Diabetes is the second largest therapeutic sector among developed countries, trailing only oncology. So how are the pharmaceutical ...

  • Posted in: Value Chain Insights

    Editor's Note: This article was updated to reflect further developments from September 2016 to end of November 2016. ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administrations (FDA) Center for Drug Evaluation and Research (CDER) has approved 16 new molecular ...

  • Posted in: Value Chain Insights

    Oncology is the largest therapeutic sector in the global pharmaceutical industry, accounting for nearly $105 billion ...

  • Posted in: Value Chain Insights

    Pfizer has agreed to acquire Medivation, a pharmaceutical company specializing in small-molecule oncology drugs, for ...

  • Posted in: Value Chain Insights

    The International Chamber of Commerce and the UN Global Compact recently formed a partnership to improve awareness, opportunities, ...

  • Posted in: Value Chain Insights

    From 3-D printing, to non-oral delivery of biologics, to advances in nanotechnology, the future for drug delivery is ...

  • Posted in: Value Chain Insights

    Orphan drugs have dominated new drug approvals over the past several years, but have they been met with commercial success? ...

  • Posted in: Value Chain Insights

    Manufacturing issues and a limited number of suppliers contributed to drug shortages for generic sterile injectable drugs, ...

  • Posted in: Value Chain Insights

    A recent analysis by Deloitte Consulting gained feedback from chief executive officers (CXOs) and chief executives-in-waiting ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administration (FDA) will hold a public meeting on August 15, 2016, to discuss proposed recommendations ...

  • Posted in: Value Chain Insights

    The policy direction of the pharmaceutical industry in the UK in the wake of Brexit took another turn when the UK Life ...

  • Posted in: Value Chain Insights

    Given the high cost of new drug development, pharmaceutical companies, researchers, and other organizations are looking ...

  • Posted in: Value Chain Insights

    So what have been the pressing developments in the pharmaceutical manufacturing value chain thus far this year? DCAT ...

  • Posted in: Value Chain Insights

    The United Kingdom’s decision to exit the European Union (EU) via a majority vote in a public referendum has created ...

  • Posted in: Value Chain Insights

    A recent analysis by KPMG points out that disruptive factors, such as new technologies, increasing competition, and pricing ...

  • Posted in: Value Chain Insights

    How pharmaceutical companies and CDMOs, CMOs, and suppliers collaborate is a key factor in being able to meet goals for ...

  • Posted in: Value Chain Insights

    Is your company properly aligned to manage risk? A recent analysis by PwC provides insight on the key characteristics ...

  • Posted in: Value Chain Insights

    The US and Europe biotechnology industries set highs in key areas, such as revenue, net income, financing, and deal values ...

  • Posted in: Value Chain Insights

    Sanofi CEO Olivier Brandicourt is pushing hard to acquire the biopharmaceutical company, Medivation, as Sanofi moves ...

  • Posted in: Value Chain Insights

    In what ways are pharmaceutical companies changing their expectations of suppliers? How can CDMOs, CMOs, and suppliers ...

  • Posted in: Value Chain Insights

    Growth in global spending on oncology therapeutics and supportive care drugs increased 11.5% on a constant-dollar basis ...

  • Posted in: Value Chain Insights

    Expansions in biologics manufacturing continue to dominate the capital expenditures of the pharmaceutical majors. So ...

  • Posted in: Value Chain Insights

    Biosimilars are a niche sector of the overall pharmaceutical market, but as the regulatory pathway becomes more defined ...

  • Posted in: Value Chain Insights

    The shareholders of Baxalta and Shire have approved the companies’ $32 billion merger with the deal now expected to close ...

  • Posted in: Value Chain Insights

    How can pharmaceutical companies and suppliers move beyond traditional paradigms in sourcing and procurement and advance ...

  • Posted in: Value Chain Insights

    At a recent investors' presentation, Eli Lilly and Company outlined its plan to potentially launch 20 new products through ...

  • Posted in: Value Chain Insights

    A recent study by A.T. Kearney identifies 12 macro trends that will play a major role in the current and future operating ...

  • Posted in: Value Chain Insights

    Having successfully floated its material sciences business, Covestro, Bayer is now positioned as a pure-play life sciences ...

  • Posted in: Value Chain Insights

    How do Procurement organizations of the large and mid-size pharmaceutical and biopharmaceutical companies measure up in ...

  • Posted in: Value Chain Insights

    Solid dosage products are a mainstay of new drug development, but parenteral drug development is on the rise. So which ...

  • Posted in: Value Chain Insights

    A recent report by the Office of the US Trade Representative highlights challenges in intellectual property rights protection ...

  • Posted in: Value Chain Insights

    The resurgence of the US pharmaceutical market is the key story in the global pharmaceutical market as the fortunes of ...

  • Posted in: Value Chain Insights

    For the pharmaceutical industry and other industrial sectors, deciding where to locate manufacturing facilities is a crucial ...

  • Posted in: Value Chain Insights

    The departure of Perrigo chairman and CEO Joseph Papa comes six months after the company successfully defended a $26 billion ...

  • Posted in: Value Chain Insights

    High-potency manufacturing continues to attract the investment dollars of CDMOs and CMOs. So what are the key projects? ...

  • Posted in: Value Chain Insights

    Total spending on medicines in the US reached $310 billion in 2015 on an estimated net price basis, up 8.5% from the ...

  • Posted in: Value Chain Insights

    Some 30 companies are actively developing biosimilar medicines for launch and are pursuing biosimilar versions of 16 ...

  • Posted in: Value Chain Insights

    A recent industry study examines the extent to which the public investment, intellectual property, and drug pricing policies ...

  • Posted in: Value Chain Insights

    Pfizer and Allergan have called off their proposed $160 billion merger citing the US Department of Treasury’s issuance ...

  • Posted in: Value Chain Insights

    By Andrew Turley, European Correspondent for DCAT Value Chain Insights (VCI) A key upcoming deadline in 2018 ...

  • Posted in: Value Chain Insights

    From tracking pharmaceutical industry growth patterns to evaluating sourcing and supply strategies for small molecules, ...

  • Posted in: Value Chain Insights

    Aprecia Pharmaceuticals has become the first company to commercially launch a FDA-approved drug manufactured using 3-D ...

  • Posted in: Value Chain Insights

    GlaxoSmithKline's (GKS) CEO Sir Andrew Witty has announced his intention to retire from the company in early 2017. The ...

  • Posted in: Value Chain Insights

    Looking back at 2015, which potential blockbusters have made the mark and remain poised for commercial success? DCAT ...

  • Posted in: Value Chain Insights

    What are the blockbusters of the future? A recent industry analysis points to the leading contenders anticipated for market ...

  • Posted in: Value Chain Insights

    What are the major regulatory changes impacting active pharmaceutical ingredient (API) manufacturing and what is the ...

  • Posted in: Value Chain Insights

    What are the major company developments impacting the pharmaceutical manufacturing value chain? DCAT's Member Company ...

  • Posted in: Value Chain Insights

    Information technology has always been important for executing sourcing and Procurement functions. But as pharmaceutical ...

  • Posted in: Value Chain Insights

    What is the optimal approach for pharmaceutical development and manufacturing? An upcoming DCAT Week '16 education program ...

  • Posted in: Value Chain Insights

    A recent analysis by the US Government Accountability Office (GAO) examined how companies are complying with US Securities ...

  • Posted in: Value Chain Insights

    Chemicals play an important part in the pharmaceutical manufacturing value chain. So what were the key issues driving ...

  • Posted in: Value Chain Insights

    A recent executive study puts risk management as a key component of overall corporate strategy. So where are companies ...

  • Posted in: Value Chain Insights

    As the number of biologic-based drugs in development and commercialization grows, a crucial issue for the industry is ...

  • Posted in: Value Chain Insights

    The pharmaceutical industry is part of the overall ecosystem for healthcare, so what key trends and issues in healthcare ...

  • Posted in: Value Chain Insights

    So what lies ahead for the generic drug market? DCAT Value Chain Insights (VCI) examines the market and upcoming regulatory ...

  • Posted in: Value Chain Insights

    Reshoring has been the talk for US manufacturing. But what do the data show? A recent analysis by A.T. Kearney ...

  • Posted in: Value Chain Insights

    Orphan drugs accounted for nearly half of new molecular entities (NMEs) approved by the FDA in 2015. Is this a winning ...

  • Posted in: Value Chain Insights

    At a recent investors' conference Ian Read, chairman and CEO of Pfizer, and Brent Saudners, CEO and president of Allergan, ...

  • Posted in: Value Chain Insights

    A recent analysis, the MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based ...

  • Posted in: Value Chain Insights

    Shire's proposed $32 billion acquisition of Baxalta, the biopharmaceutical company spun off from Baxter in 2015, would ...

  • Posted in: Value Chain Insights

    In 2015, the US Food and Drug Administration's Center for Drug Evaluation and Research approved 45 new molecular entities ...

  • Posted in: Value Chain Insights

    Patient adherence is an important consideration when designing drug-delivery systems, devices, and related components ...

  • Posted in: Value Chain Insights

    So what is on the horizon for the pharmaceutical industry for 2016? DCAT Value Chain Insights (VCI) highlights 10 key ...

  • Posted in: Value Chain Insights

    Just weeks after Pfizer and Allergan announced a $160 billion mega merger, the supply side is bracing for its mega deal: ...

  • Posted in: Value Chain Insights

    As 2015 comes to a close, a crucial question for procurement organizations is how they performed in 2015 in delivering ...

  • Posted in: Value Chain Insights

    As 2015 begins to wind down, the US Food and Drug Administration's Center for Drug Research and Evaluation has approved ...

  • Posted in: Value Chain Insights

    The IMS Institute for Healthcare Informatics projects that total spending on medicines will reach $1.4 trillion by 2020 ...

  • Posted in: Value Chain Insights

    As we begin the final month of 2015, what have been the top stories of 2015 thus far? DCAT Value Chain Insights (VCI) ...

  • Posted in: Value Chain Insights

    Pfizer's pending $160 billion acquisition of Allergan would be the largest deal in pharmaceutical industry history, so ...

  • Posted in: Value Chain Insights

    After Mylan failed to secure the necessary shares for its proposed $26 billion takeover of Perrigo last week, what is ...

  • Posted in: Value Chain Insights

    Roche's announcement last week that it plans to close four small-molecule manufacturing facilities is the latest move ...

  • Posted in: Value Chain Insights

    The US Federal Trade Commission (FTC) is among those asking the US Food and Drug Administration (FDA) to reconsider its ...

  • Posted in: Value Chain Insights

    Sanofi CEO Olivier Brandicourt has put forth a plan to refocus and reshape Sanofi with the goal of generating compound ...

  • Posted in: Value Chain Insights

    Shire's proposed $5.9 billion acquisition of Dyax, a company specializing in drug development for rare diseases, is the ...

  • Posted in: Value Chain Insights

    Pfizer and Allergan have confirmed that the companies are in preliminary friendly discussions in relation to a potential ...

  • Posted in: Value Chain Insights

    Despite increased penetration of biologics and small-molecules delivered via parenterally or in other routes, solid dosage ...

  • Posted in: Value Chain Insights

    The European Medicines Agency (EMA) issued a report to highlight the agency's work, including inspections of good manufacturing ...

  • Posted in: Value Chain Insights

    The Trans-Pacific Partnership (TPP) agreement has engendered debate with the pharmaceutical industry as the industry ...

  • Posted in: Value Chain Insights

    Supplier-led innovation is an important part of building strategic partnerships. GlaxoSmithKline is among the companies ...

  • Posted in: Value Chain Insights

    Small molecules still constitute the majority of commercial drugs, but biologics' inroads into the pharmaceutical market ...

  • Posted in: Value Chain Insights

    Merck KGaA is using internal investment, alliances, and mergers and acquisitions as a means to grow two of its major ...

  • Posted in: Value Chain Insights

    The International Conference on Harmonization (ICH) is an important mechanism for facilitating harmony in pharmaceutical ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administration (FDA) has approved 27 new molecular entities thus far in 2015, with five NME approvals ...

  • Posted in: Value Chain Insights

    Although continuous manufacturing is common in other industrial production, such as food processing and petrochemicals, ...

  • Posted in: Value Chain Insights

    A recent study from the IMS Institute for Healthcare Informatics estimates there are now more than 165,000 mobile health ...

  • Posted in: Value Chain Insights

    Having the right governance model for external partnerships is critical for a successful outsourcing relationship. So ...

  • Posted in: Value Chain Insights

    Partnerships are a mainstay in drug development, but the pharmaceutical industry is entering into a new era of innovation ...

  • Posted in: Value Chain Insights

    Immuno-oncology is a hot area in the pharmaceutical market, led by recent potential blockbuster product introductions ...

  • Posted in: Value Chain Insights

    Paul M. Bisaro, executive chairman and Brent Sanders, CEO and president, are leading Allergan through its transformation ...

  • Posted in: Value Chain Insights

    From new approaches for patient adherence, to advances in anti-counterfeiting technology, and innovation in for protecting ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administration (FDA) held a public meeting in late August to gain feedback on its proposed quality ...

  • Posted in: Value Chain Insights

    The OTC market is coming off an active year in 2014 and 2015 to date, which included two mega deals: the formation of ...

  • Posted in: Value Chain Insights

    Growth in the injectables market is being driven by generic injectables, which are outpacing growth of innovator injectables ...

  • Posted in: Value Chain Insights

    Successful supplier relationships are crucial for executing a company’s overall business strategy. How does the pharmaceutical ...